An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer

Epidermal growth factor receptor (EGFR) pathway has been shown to play a crucial role in several inflammatory conditions and host immune-inflammation status is related to tumor prognosis. This study aims to evaluate the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The inflammatory signature was assessed on 123 R/M HNSCC patients, enrolled in the multicenter trial B490 receiving first-line cetuximab plus platinum-based chemotherapy. The primary endpoint of the study was progression free survival (PFS), while secondary endpoints were overall survival (OS) and objective response rate (ORR). The patient population was subdivided into 3 groups according to the signature score groups. The four-genes-signature proved a significant prognostic value, resulting in a median PFS of 9.2 months in patients with high vs. 6.2 months for intermediate vs. 3.9 months for low values (p = 0.0016). The same findings were confirmed for OS, with median time of 18.4, 13.4, and 7.5 months for high, intermediate, and low values of the score, respectively (p = 0.0001). When ORR was considered, the signature was significantly higher in responders than in non-responders (p = 0.0092), reaching an area under the curve (AUC) of 0.65 (95% CI: 0.55–0.75). Our findings highlight the role of inflammation in the response to cetuximab and chemotherapy in R/M-HNSCC and may have translational implications for improving treatment selection.

[1]  P. Saintigny,et al.  Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity. , 2021, Oral oncology.

[2]  S. Lippman,et al.  Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. , 2021, The Lancet. Oncology.

[3]  G. Frampton,et al.  Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression , 2021, Journal for ImmunoTherapy of Cancer.

[4]  G. Gao,et al.  A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients , 2021, Annals of translational medicine.

[5]  P. Sharma,et al.  Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer , 2021, Clinical Cancer Research.

[6]  Sung-Bae Kim,et al.  Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Grégoire,et al.  Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  J. Furuse,et al.  Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma , 2020, Journal of hepatology.

[9]  P. Pauwels,et al.  Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status , 2020, British Journal of Cancer.

[10]  S. Pignata,et al.  Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience , 2020, Cells.

[11]  Hung-Ming Wang,et al.  Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.

[12]  Zhenggang Zhu,et al.  Pre-treatment inflammatory biomarkers predict early treatment response and favorable survival in patients with metastatic colorectal cancer who underwent first line cetuximab plus chemotherapy , 2019, Cancer management and research.

[13]  D. Schadendorf,et al.  Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma , 2019, Clinical Trials.

[14]  J. Califano,et al.  Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics , 2019, Clinical Cancer Research.

[15]  Ge Zhou,et al.  Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma , 2018, British Journal of Cancer.

[16]  Guang Li,et al.  Prognostic Role of PD-1/PD-L1 Expression in Patients with Head And Neck Cancer and Its Correlation with HPV/p16 , 2018, International Journal of Radiation Oncology*Biology*Physics.

[17]  K. Li,et al.  The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. , 2018, Oral oncology.

[18]  M. Gerlinger,et al.  Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer , 2018, bioRxiv.

[19]  F. Marincola,et al.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) , 2018, Journal of Immunotherapy for Cancer.

[20]  Xuelei Ma,et al.  Pre-treatment inflammatory indexes as predictors of survival and cetuximab efficacy in metastatic colorectal cancer patients with wild-type RAS , 2017, Scientific Reports.

[21]  F. Caponigro,et al.  A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Willems,et al.  The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis , 2017, Oncoimmunology.

[23]  G. Milano,et al.  Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy , 2017, Cancer Immunology, Immunotherapy.

[24]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .

[25]  L. De Cecco,et al.  Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab , 2016, Clinical Cancer Research.

[26]  G. Milano,et al.  The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients. , 2015, Critical reviews in oncology/hematology.

[27]  R. Seethala,et al.  STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients , 2015, Cancer Immunology Research.

[28]  R. Ferris,et al.  EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3 , 2014 .

[29]  R. Ferris,et al.  EGFR-mediated tumor immunoescape , 2013, Oncoimmunology.

[30]  F. Hirsch,et al.  Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. , 2013, European journal of cancer.

[31]  R. Ferris,et al.  Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients , 2013, Clinical Cancer Research.

[32]  T. Teknos,et al.  Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. , 2012, Surgery.

[33]  S. Störkel,et al.  Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.